Apr 06, 2022 / 12:30PM GMT
Operator
Good morning, and welcome to the BioXcel Therapeutics conference call to discuss the FDA approval of IGALMI. (Operator Instructions)
Just to remind everyone, certain matters discussed in today's conference call and/or answers that may be given to questions asked are forward-looking statements subject to risks and uncertainties related to future events and/or the future financial performance of the company. Actual results could differ materially from those anticipated in these forward-looking statements. Risk factors that may affect results are detailed in the company's most recent public filings with the U.S. Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2021, which can be found at www.bioxceltherapeutics.com or on www.sec.gov. As a reminder, today's conference is being recorded, and a supplemental presentation is available on the Investors section of BioXcel's website.
Joining us on today's
BioXcel Therapeutics Inc To Discuss The FDA Approval Of IGALMI Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot